"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
The SIQ for this article will be revealed
sars-cov-2, covid-19, encephalopathy, leptomeningeal enhancement, generalized tonic clonic seizures, altered mental state, emergency medicine physician, icu patients, acute encephalitis
Abdullah Baksh , Alia Hadid, Thiagarajan Jaiganesh
Cite this article as: Baksh A, Hadid A, Jaiganesh T (August 20, 2022) COVID-19 Encephalopathy Presenting As New-Onset Seizure: A Case Report. Cureus 14(8): e28204. doi:10.7759/cureus.28204
Since its outbreak, it's been well-documented that coronavirus disease 2019 (COVID-19) can present with wide variety of neurological manifestations in absence of the usual respiratory symptoms. We report one such severe neurological manifestation of SARS-CoV-2 infection. To our knowledge, this is the first reported case of COVID-19 encephalopathy with CSF and MRI findings in the United Arab Emirates. We present a case of a 52-year-old female who presented with complaints of altered mentation, anosmia, headache, dizziness, weakness, lethargy, and vomiting. While in the emergency department she developed two generalized tonic-clonic seizure episodes, a more pronounced delirium, and tachypnea which required intubation. She was then admitted to the intensive care unit (ICU). She was COVID-19 positive and subsequent MRI revealed encephalopathy. She was discharged from ICU and was under long-term care at the time of case documentation.
Novel coronavirus infection in the elderly, especially those with other comorbidities, is more likely to render grave illness [1,2]. It is in this population where the greater risk of developing acute encephalopathy and altered mental status lies. We hereby report a case of coronavirus disease 2019 (COVID-19) encephalopathy in which generalized tonic-clonic seizures were the presenting feature of the disease.
A 52-year-old diabetic female arrived at our emergency department (ED) with a three-day history of headaches, anosmia, dizziness, weakness, lethargy, vomiting, and appetite loss. The patient denied fever, photophobia, neck pain, flu-like symptoms, and shortness of breath. Past medical, surgical, and allergic history was of no significance. She had no history of sick contacts and was not a smoker. On arrival to the ED, she was tachypneic (respiratory rate {RR}: 20 breaths per minute {bpm}), tachycardic (heart rate {HR}: 117 beats per minute {bpm}), was saturating well on room air (SpO2: 99%), and had a Glasgow Coma Scale (GCS) of 14/15. General cardiorespiratory and neurological examination was otherwise unremarkable.
The initial impression was pneumonia with respiratory distress based on elevated inflammatory markers and chest x-ray finding of bilateral pulmonary consolidations (Figure 1). The patient was empirically treated with antibiotics as per local protocols.
Twenty minutes later, the patient developed two episodes of generalized tonic-clonic seizures and required intubation. CT thorax showed features typical of COVID-19 pneumonia with a severity score of moderate (Figure 2).
COVID-19 nasopharyngeal swab test (performed by the MDx 2019 n-COV reverse transcription polymerase chain reaction {RT-PCR}) was positive and COVID-19 prognostic markers were all elevated (Table 1).
LDH: lactate dehydrogenase; CRP: c-reactive protein; COVID-19: coronavirus disease 2019; HI: high
The patient was admitted to the ICU as a case of COVID-19 pneumonia with sepsis and possible secondary meningitis, encephalitis, and/or encephalopathy. Following her positive COVID-19 nasopharyngeal swab result, she was started on COVID-19 therapy as per local protocol which, at the time, included hydroxychloroquine sulfate and favipiravir.
A full workup, including CT head, was done to rule out other correctable causes of seizures, and they were all unremarkable. Given the picture of high inflammatory markers, new seizure activity, and a normal CT brain, lumbar puncture was done and she was empirically treated with acyclovir, ceftriaxone, and vancomycin for meningoencephalitis.
Subsequently, lumbar puncture result revealed a WBC count of 10/mm3 with a lymphocyte predominance (73%), high protein (0.57 g/L), and glucose (124 mmol/L), and a negative CSF culture, pointing to encephalopathy rather than encephalitis (Table 2).
Due to unavailability of CSF PCR analysis, presence of COVID-19 virus in CSF could not be ruled out. During the course of the ICU stay, GCS remained 3/15 without sedation, so status epilepticus was suspected and treatment with levetiracetam and lacosamide was started. EEG could not be done because of risk of exposure as per hospital protocols. The repeat CT brain was unremarkable, and she was scheduled for an MRI of the brain. MRI brain revealed extensive leptomeningeal enhancement and bilateral symmetrical basal ganglia enhancement, suggestive of meningoencephalopathy (Figure 3).
T1-weighted image pre-contrast (left) and T1-weighted image post-contrast (right).
Eventually, given that her Glasgow Coma Score (GCS) remained 4/15 off paralytics and sedatives, tracheostomy was done and she was shifted to a long-term care facility once she became COVID-negative, where she resides to date.
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has neurotropic and neuroinvasive abilities. Neurological problems in patients with coronavirus infection range from disorders of smell and taste to encephalopathy, seizures, and strokes, as reported by numerous studies [3]. Our report shows yet another case of COVID-19-associated neurological manifestations, mainly encephalopathy.
The mechanism by which SARS-CoV-2 causes encephalopathy is currently unknown. The most commonly accepted notion is the hematogenous spread of viral particles into the CNS via circulating lymphocytes [4]. Another theory is viral movement in a retrograde fashion across the cribriform plate into the CNS [4]. In addition to viral infection, host immune response causing a cytokine storm leading to damage in the blood-brain barrier, increasing leukocyte migration and inflammation, maybe another mechanism causing encephalopathy [4]. It has been proposed that SARS-CoV-2 can infiltrate the brainstem leading to dysfunction of the cardiorespiratory centers of the brainstem, which explains the deterioration of respiratory effort and a subsequent need for ventilation [5].
Amid the numerous common presentations of COVID-19, a seizure is an uncommon initial neurological presentation [6]. The most extensive retrospective case series encompassing 1,043 COVID-19-positive admitted patients found that only four (0.4%) of the patients presented with new-onset seizures [7].
Leptomeningeal enhancement on MRI is an essential differentiator between a diagnosis of COVID-19 encephalopathy and hypoxic encephalopathy. As in our case, leptomeningeal enhancement was noted in eight out of 13 patients undergoing MRI due to unexplained encephalopathy features [8].
Another case series provided evidence of hypoxic brain damage detected on MRI, which revealed T2-fluid attenuated inversion recovery (FLAIR) hyperintensities, and came to the conclusion that hypoxic damage more frequently presents with these findings on MRI rather than leptomeningeal enhancement induced directly by SARS-CoV-2 [9].
Due to the unavailability (CSF PCR analysis) and concerns regarding the spread of infection, electroencephalogram (EEG) was not done. However, SARS-CoV-2 CSF PCR analysis has been found to be specific [10], but not sensitive in detecting direct viral invasion of the central nervous system [11,12]. Also, there is a lack of evidence supporting specific stereotyped EEG patterns in patients with COVID-19 encephalopathy, nor are any abnormal waveforms predictive of a neurological prognosis for this population [13,14].
As compared to general COVID-19 therapies including but not limited to glucocorticoids, remdesivir, interleukin-6 (IL-6) pathway inhibitors, and other antibody therapies [15], the management of COVID-19 encephalopathy, per se, remains to be entirely supportive, with treatment being directed towards the underlying cause.
Our patient presented early in the pandemic when hydroxychloroquine and favipiravir were considered a potential treatment modality. She did not receive glucocorticoids or immunomodulator therapy which were later studied and recommended [15]. There are reported case series where patients with severe encephalopathy improved clinically after receiving corticosteroids, immunotherapy, and plasma exchange [16,17]. There are similar reported cases of COVID-19 encephalopathy, where pulse therapy of high-dose corticosteroids showed promising results [16,18]. However, further research is needed to establish the effectiveness and responsiveness of corticosteroid therapy in encephalopathy [16].
COVID-19 encephalopathy patients tend to have increased morbidity and mortality, similar to our case [19]. One study reported that COVID-19 encephalopathy patients had longer durations of hospital stay, worse functional impairment at discharge, and higher 30-day mortality rate compared to COVID-19 patients without encephalopathy (22% vs 3%) [19]. Further long-term outcomes remain to be elucidated.
The diagnosis of COVID-19 encephalopathy was established for our patient based on the fact that her neurological status declined despite the improvement of her general condition, and other major causes of CNS affection were ruled out. COVID-19 encephalopathy is potentially a severe neurological manifestation of the SARS-CoV-2 infection and due to its highly variable presentation, clinicians need to have a high index of suspicion. To better understand the neuropathological capabilities of COVID-19, its long-term impact on patients with pre-existing comorbidities and further treatment modalities, ongoing investigations are recommended.
Emergency Department, Tawam Hospital, Al Ain, ARE
Emergency Department, Tawam Hospital, Al Ain, ARE
Emergency Department, Tawam Hospital, Al Ain, ARE
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
We would like to extend our gratitude to the clinicians and healthcare staff at Tawam Hospital who have worked for endless hours with patients diagnosed with COVID-19. We would also like to thank Dr. Ahmed Eltayeb, Dr. Ali, Dr. Ayman, Dr. Nour, Dr. Sneha, and Dr. Suzan for their support and feedback.
Baksh A, Hadid A, Jaiganesh T (August 20, 2022) COVID-19 Encephalopathy Presenting As New-Onset Seizure: A Case Report. Cureus 14(8): e28204. doi:10.7759/cureus.28204
Peer review began: October 26, 2021 Peer review concluded: August 16, 2022 Published: August 20, 2022
© Copyright 2022 Baksh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
T1-weighted image pre-contrast (left) and T1-weighted image post-contrast (right).
LDH: lactate dehydrogenase; CRP: c-reactive protein; COVID-19: coronavirus disease 2019; HI: high
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.
This link will take you to a third party website that is not affiliated with Cureus, Inc. Please note that Cureus is not responsible for any content or activities contained within our partner or affiliate websites.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
High ratings should be reserved for work that is truly groundbreaking in its respective field. Anything above 5 should be considered above average. While all registered Cureus users can rate any published article, the opinion of domain experts is weighted appreciably more than that of non-specialists. An article’s SIQ™ will appear alongside the article after being rated twice and is recalculated with each additional rating.
Visit our SIQ™ page to find out more.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
Already have an account? Sign in.
Please note that by doing so you agree to be added to our monthly email newsletter distribution list.
By joining Cureus, you agree to our Privacy Policy and Terms of Use.